Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Symptomatic Intracranial Atherosclerosis
NCT03507374Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alirocumab in intracranial atherosclerosis (ICAD) and ischemic stroke (2 arms), sponsored by University of Utah. Primary endpoint: Vessel Wall MRI at Day 365. Started Oct 2018; status: terminated.
02
Drugs
alirocumab
03
Conditions
intracranial atherosclerosis (ICAD)ischemic stroke
Beyond the preview
Go deeper on NCT03507374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507374.